^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Ovarian Cancer |
| Drug: | Votrient (pazopanib) (Multi-tyrosine kinase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Excerpt:
The NCCN panel recommends postremission paclitaxel or pazopanib (category 2B) for management of stage II to IV...
